Axon Therapies
@AxonTherapies
Followers
80
Following
73
Media
26
Statuses
113
Developing frontline heart failure therapies to restore volume balance, stop disease progression and improve symptoms. #SAVM with the #SateraAblation System
New York, NY
Joined September 2020
The paper discusses the methods & results of the study, including detail on the #SAVM procedure and mechanism of action, as well as positive clinical outcomes in the initial roll-in cohort. Take a look! https://t.co/m9wL4zFK8u
@JCardFail #HFpEF #CardioTwitter
onlinejcf.com
Splanchnic vasoconstriction augments transfer of blood volume from the abdomen into the thorax, which may increase filling pressures and hemodynamic congestion in patients with noncompliant hearts....
0
1
3
This recently published paper in @JCardFail provides an excellent overview of our REBALANCE-HF study, the largest randomized device feasibility study in #HFpEF... https://t.co/m9wL4zFK8u
#CardioTwitter
onlinejcf.com
Splanchnic vasoconstriction augments transfer of blood volume from the abdomen into the thorax, which may increase filling pressures and hemodynamic congestion in patients with noncompliant hearts....
1
1
3
The session is Friday from 9:20 – 10:40 CET: "Neuromodulation in the Management of Heart Failure and its Comorbidities: Diabetes, Sleep Apnea, Hypertension and Arrhythmias"
csi-congress.org
0
0
0
Attending @CSIcongress' Focus D-HF 2023 this weekend in Germany? Hear from Axon Senior Clinical Advisor & Board Member Howard Levin, MD about splanchnic nerve modulation in #HFpEF. #SAVM #HeartFailure
csi-congress.org
1
1
5
For HF clinicians with curiosity about the REBALANCE-HF trial, the results shared at #HFSA2023 + what this mechanism could mean for patients with #HFpEF, this video is a must-view deep-dive. @FudimMarat @mvaduganathan @SJGreene_md #DontMissABeat #SAVM
hcplive.com
Hosts are joined by Marat Fudim, MD, MHS, of Duke, to discuss the REBALANCE-HF trial, which examined endovascular ablation of the right greater splanchnic nerve in heart failure with preserved...
0
1
7
As we break for #Thanksgiving, we want to share our heartfelt thanks to the many people who have given time, effort, belief & expertise to our mission this year, helping to advance the research into our novel #SAVM therapy. Thank you! ❤️Your friends at Axon #HappyThanksgiving
0
0
0
See @GoHealio's article about our findings from a primary analysis of the REBALANCE-HF randomized trial, presented at @HFSA's Annual Meeting in Oct., showing splanchnic ablation (#SAVM) could improve exercise capacity & PCWP in most patients with #HFpEF.
healio.com
Researchers identified a subgroup of patients with HF with preserved ejection fraction and elevated pulmonary capillary wedge pressure that may benefit from splanchnic ablation for volume managemen...
0
0
1
It was very exciting to present primary results & responder analysis of the REBALANCE-HF study at #HFSA2023 earlier this month. Big thanks to @FudimMarat for presenting the results, to @KSharmaMD for her thoughtful response, and to all of our investigators + their teams. #SAVM
0
2
6
Our Rebalance-HF trial – investigating the safety & effectiveness of the #SAVM procedure – is another option in addition to SGLT2s to consider for patients who are age 40+, diagnosed with chronic HF, & not diagnosed with advanced HF. More info here:
pubmed.ncbi.nlm.nih.gov
The preliminary open-label results from the multicentre REBALANCE-HF roll-in cohort support the safety and efficacy of SAVM in HFpEF. The findings require confirmation in the ongoing randomized,...
0
0
0
In patients hospitalized with Heart Failure with Preserved Ejection Fraction (#HFpEF), poor outcomes are exceedingly common, and neither medical nor surgical interventions are well-established routine practice for this patient population.
healio.com
Patients with heart failure with preserved ejection fraction and those with HF and mildly reduced EF experienced similarly poor outcomes and mortality rates over 12 months follow-up after HF hospit...
1
0
0
Check out this informative background information on #HFpEF management, co-authored by @LitwinSheldon, one of the investigators of our Rebalance-HF study. #SAVM
medscape.com
Although proven medical therapies for HFpEF are few, a stepwise set of management practices can help optimize care for patients with this condition.
0
0
3
If you're attending the Charleston #HFpEF Conference this weekend, come see us! Hosted by @MedUnivSC, a leading patient enroller in our Rebalance-HF study, this conf. is a great opportunity to learn about potential new approaches to treating this unique patient population. #SAVM
0
0
1
What is “heart failure with preserved ejection fraction”? Here’s a great primer from @medpagetoday that discusses the epidemiology and pathogenesis of #HFpEF:
medpagetoday.com
The basics on pathogenesis and epidemiology
0
0
0
As the authors note: “HFpEF is one of the most pressing diagnostic and therapeutic challenges in clinical medicine today given its increasing prevalence, underdiagnosis, poor prognosis, limited therapeutic options, and substantial burden on the health care system worldwide.”
1
0
0
#HFpEF can be hard to diagnose, leading to delays in treatment and potentially worse outcomes for patients. This new scoring system is a step in the right direction!👏 https://t.co/zLAIUhgvEO
0
0
0
Looking for a simple way to identify #HFpEF? Clinicians involved in our Rebalance-HF study – Margaret Redfield at @MayoClinic + Barry Borlaug at @NorthwesternU – have developed & validated a scoring system called the H2FPEF score to estimate the probability of underlying HFpEF...
1
0
0
#20 The aim for the REBALANCE HF pilot RCT is to help us determine the ❓ideal phenotype❓ for Splanchnic Nerve Modulation. We will then embark on a pivotal RCT later this year!🌟 If you are interested and want to be a site please reach out!
2
2
15